Literature DB >> 9279003

Analysis of the distribution of glycine and GABA in amacrine cells of the developing rabbit retina: a comparison with the ontogeny of a functional GABA transport system in retinal neurons.

D K Crook1, D V Pow.   

Abstract

The objectives of this study were to (1) determine whether the glycinergic and GABAergic amacrine cells in the developing rabbit retina were neurochemically distinct at birth, (2) determine if the ratio of GABAergic to glycinergic amacrine cells was constant during development, (3) determine whether the capacity to take up a GABA analogue was restricted to GABAergic neurons, and (4) whether initiation of GABA transport into GABAergic neurons preceded the presence of a content of GABA in these neurons. We have used a novel strategy to immunolocalize a non-endogenous GABA analogue, gamma-vinyl GABA, which is taken up into neurons by a GABA transporter. Examination of serial semithin resin-embedded sections of neonatal rabbit retinae that had been immunolabelled for glycine, GABA or gamma-vinyl GABA revealed that at 1 day postnatum, 60% of amacrine cells contain glycine but not GABA and did not accumulate gamma-vinyl GABA, which is similar to the percentage of glycinergic amacrine cells in the adult retina. The vast majority of the remaining amacrine cells contained GABA and many also transported gamma-vinyl GABA; however, a significant number of GABA-containing cells failed to accumulate gamma-vinyl GABA suggesting that possession of a content of GABA did not have to be preceded by, or be concomitant with, the presence of a GABA transport system. By 10 days postnatum, over 99% of GABA-containing amacrine cells also transported gamma-vinyl GABA indicating their functional maturity. Analysis of the horizontal cells revealed no evidence for uptake of gamma-vinyl GABA, but another GABA analogue, diaminobutyric acid, which is a substrate both for the neuron-associated GABA transporter and the glial GABA transporter, was accumulated into some horizontal cells at 21 days postnatum, a time point when these cells also contain endogenous GABA. We conclude that amacrine cells are committed to being GABAergic or glycinergic at, or prior to birth, and that in some amacrine cells, expression of a content of GABA may occur prior to the capacity to transport GABA. Conversely, in some ganglion cells transport of gamma-vinyl GABA may precede a content of GABA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9279003     DOI: 10.1017/s0952523800012700

Source DB:  PubMed          Journal:  Vis Neurosci        ISSN: 0952-5238            Impact factor:   3.241


  7 in total

1.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

2.  Development of presynaptic inhibition onto retinal bipolar cell axon terminals is subclass-specific.

Authors:  Timm Schubert; Daniel Kerschensteiner; Erika D Eggers; Thomas Misgeld; Martin Kerschensteiner; Jeff W Lichtman; Peter D Lukasiewicz; Rachel O L Wong
Journal:  J Neurophysiol       Date:  2008-04-24       Impact factor: 2.714

3.  Survey on amacrine cells coupling to retrograde-identified ganglion cells in the mouse retina.

Authors:  Ji-Jie Pang; David L Paul; Samuel M Wu
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-01       Impact factor: 4.799

4.  Vesicular gamma-aminobutyric acid transporter expression in amacrine and horizontal cells.

Authors:  Juan G Cueva; Silke Haverkamp; Richard J Reimer; Robert Edwards; Heinz Wässle; Nicholas C Brecha
Journal:  J Comp Neurol       Date:  2002-04-08       Impact factor: 3.215

5.  Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms.

Authors:  Jason T Lerner; Noriko Salamon; Raman Sankar
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-08       Impact factor: 2.570

6.  Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy.

Authors:  Sivan Durbin; Giuseppe Mirabella; J Raymond Buncic; Carol A Westall
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-11       Impact factor: 4.799

Review 7.  Visual field defects with vigabatrin: epidemiology and therapeutic implications.

Authors:  R Kälviäinen; I Nousiainen
Journal:  CNS Drugs       Date:  2001       Impact factor: 6.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.